Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.

- Study data to be presented (Presentation date/ time:USA Eastern time zone)

Abstract No.: 370

Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active

        Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo-Controlled*

        Phase 2A Study     

        Presentation date/ time: May 4, 2014, 1:36-1:46PM, Oral presentation

*Randomized double-blind, placebo-controlled study

Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.

About Ajinomoto Pharmaceuticals Co., Ltd.

Representative Director,President & CEO: Takashi Nagamachi

Headquarters, Chuo-ku, Tokyo

Source: Ajinomoto Pharmaceuticals Co., Ltd.